Anne Blaes

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4997115/publications.pdf

Version: 2024-02-01

293460 232693 2,585 65 24 48 citations h-index g-index papers 68 68 68 4658 docs citations times ranked citing authors all docs

#	Article	IF	Citations
1	Crossâ€sectional study of psychosocial wellâ€being among lesbian, gay, bisexual, and heterosexual gynecologic cancer survivors. Cancer Reports, 2022, 5, e1461.	0.6	9
2	Financial Burden of Drugs Prescribed for Cancer-Associated Symptoms. JCO Oncology Practice, 2022, 18, 140-147.	1.4	23
3	Defining cardiovascular toxicities of cancer therapies: an International Cardio-Oncology Society (IC-OS) consensus statement. European Heart Journal, 2022, 43, 280-299.	1.0	213
4	Research contributions from the First Cancer Center Survivorship Research Forum. Journal of Cancer Survivorship, 2022, 16, 1-3.	1.5	4
5	Perception of Telehealth During the COVID-19 Pandemic Among Survivors of Gynecologic Cancer. Oncologist, 2022, 27, 512-515.	1.9	4
6	Five-Year Cumulative Incidence of Axillary Web Syndrome and Comparison in Upper Extremity Movement, Function, Pain, and Lymphedema in Survivors of Breast Cancer With and Without Axillary Web Syndrome. Archives of Physical Medicine and Rehabilitation, 2022, 103, 1798-1806.	0.5	5
7	Interactions between physical activity and type of cancer treatment received on associations with psychosocial outcomes among gynecologic cancer survivors. Gynecologic Oncology, 2022, , .	0.6	0
8	Finding the Lowest-Cost Pharmacy for Cancer Supportive Care Medications: Not So Easy. JCO Oncology Practice, 2022, 18, e1342-e1349.	1.4	5
9	Training and Career Development in Cardio-Oncology Translational and Implementation Science. Heart Failure Clinics, 2022, 18, 503-514.	1.0	1
10	Cardiovascular Disease in Breast Cancer Survivors: An Important Topic in Breast Cancer Survivorship. Journal of the National Cancer Institute, 2021, 113, 105-106.	3.0	12
11	Response to Schoormans. Journal of the National Cancer Institute, 2021, 113, 214-215.	3.0	1
12	Cardiovascular Care of the Oncology Patient During COVID-19: An Expert Consensus Document From the ACC Cardio-Oncology and Imaging Councils. Journal of the National Cancer Institute, 2021, 113, 513-522.	3.0	13
13	A Randomized Phase IIb Study of Low-dose Tamoxifen in Chest-irradiated Cancer Survivors at Risk for Breast Cancer. Clinical Cancer Research, 2021, 27, 967-974.	3.2	12
14	Impact of body mass index on pathological complete response following neoadjuvant chemotherapy in operable breast cancer: a meta-analysis. Breast Cancer, 2021, 28, 618-629.	1.3	20
15	Cancer Treatment-Induced Accelerated Aging in Cancer Survivors: Biology and Assessment. Cancers, 2021, 13, 427.	1.7	39
16	Reaching Across the Aisle: Cardio-Oncology Advocacy and Program Building. Current Oncology Reports, 2021, 23, 64.	1.8	11
17	Interactions between physical activity and clinical factors in the relationship with quality of life and emotional health outcomes of gynecologic cancer survivors. Gynecologic Oncology, 2021, 162, S191.	0.6	0
18	Genetic variants predictive of chemotherapy-induced peripheral neuropathy symptoms in gynecologic cancer survivors. Gynecologic Oncology, 2021, 163, 578-582.	0.6	2

#	Article	IF	Citations
19	The association between cancer care coordination and quality of life is stronger for breast cancer patients with lower health literacy: A Greater Plains Collaborative study. Supportive Care in Cancer, 2020, 28, 887-895.	1.0	8
20	The Impact of Bariatric Surgery on Breast Cancer Recurrence: Case Series and Review of Literature. Obesity Surgery, 2020, 30, 780-785.	1.1	17
21	Trichomegaly Associated with Panitumumab. New England Journal of Medicine, 2020, 383, e94.	13.9	4
22	How to Follow, Manage and Treat CardiacÂDysfunction in Patients With Her2+ Breast Cancer. JACC: CardioOncology, 2020, 2, 661-665.	1.7	4
23	Cardioâ€oncology care in the era of the coronavirus disease 2019 (COVIDâ€19) pandemic: An International Cardioâ€Oncology Society (ICOS) statement. Ca-A Cancer Journal for Clinicians, 2020, 70, 480-504.	157.7	29
24	Cardiovascular toxicity in patients treated with immunotherapy for metastatic non-small cell lung cancer: A SEER-medicare study. Lung Cancer, 2020, 150, 172-177.	0.9	9
25	Impact of adjuvant chemotherapy on outcomes in appendiceal cancer. Cancer Medicine, 2020, 9, 3400-3406.	1.3	27
26	Perspectives of cancer patients and their health during the COVID-19 pandemic. PLoS ONE, 2020, 15, e0241741.	1.1	59
27	Is it time to include cancer in cardiovascular risk prediction tools?. Lancet, The, 2019, 394, 986-988.	6.3	31
28	Factors associated with genetic testing in a cohort of breast cancer survivors. Breast Journal, 2019, 25, 1241-1244.	0.4	6
29	Lessons From Primary Cardiac Prevention Trials During Trastuzumab Therapy. Journal of the American College of Cardiology, 2019, 73, 2869-2871.	1.2	9
30	Low-Dose Tamoxifen (LDTam) As a Breast Cancer (BC) Risk-Reduction Strategy in Lymphoma Survivors Exposed to Chest Radiation Therapy (RT) during Adolescence/Young Adulthood - a Randomized, Placebo-Controlled Double Blinded Phase Ilb Trial. Blood, 2019, 134, 2843-2843.	0.6	2
31	Development of a Mobile Health Intervention to Promote Papanicolaou Tests and Human Papillomavirus Vaccination in an Underserved Immigrant Population: A Culturally Targeted and Individually Tailored Text Messaging Approach. JMIR MHealth and UHealth, 2019, 7, e13256.	1.8	11
32	A pilot study evaluating chemotherapy tolerability for breast cancer patients who have received prior treatment and chest radiation for Hodgkin Lymphoma. Cancer Treatment and Research Communications, 2018, 15, 1-6.	0.7	2
33	Distribution of 21-Gene Recurrence Scores Among Breast Cancer Histologic Subtypes. Archives of Pathology and Laboratory Medicine, 2018, 142, 735-741.	1.2	13
34	Arterial elasticity as a risk factor for early cardiovascular disease among testicular cancer survivors treated with platinum-based chemotherapy: a cross-sectional pilot study. Vascular Health and Risk Management, 2018, Volume 14, 205-211.	1.0	2
35	Tumor grade and progesterone receptor status predict 21-gene recurrence score in early stage invasive breast carcinoma. Breast Cancer Research and Treatment, 2018, 172, 671-677.	1.1	18
36	Left Ventricular Ejection Fraction Monitoring Adherence Rates. JACC: Cardiovascular Imaging, 2018, 11, 1094-1097.	2.3	3

#	Article	IF	CITATIONS
37	Cardio-oncology Related to Heart Failure. Heart Failure Clinics, 2017, 13, 367-380.	1.0	44
38	Geriatric Cardio-oncology., 2017,, 281-301.		0
39	Cardiac safety profile of patients receiving high cumulative doses of pegylated-liposomal doxorubicin: use of left ventricular ejection fraction is of unproven value. Cancer Chemotherapy and Pharmacology, 2017, 80, 787-798.	1.1	28
40	Incidence, Diagnosis, and Treatment of Cardiac Toxicity From Trastuzumab in Patients With Breast Cancer. Current Breast Cancer Reports, 2017, 9, 173-182.	0.5	26
41	Vascular function in breast cancer survivors on aromatase inhibitors: a pilot study. Breast Cancer Research and Treatment, 2017, 166, 541-547.	1.1	32
42	Cardiac Imaging Methods for Chemotherapy-related Cardiotoxicity Screening and Related Radiation Exposure: Current Practice and Trends. Anticancer Research, 2017, 37, 2445-2449.	0.5	10
43	Left Ventricular Ejection Fraction Screening and Clinical Decision-making in Metastatic HER2-positive Breast Cancer. Anticancer Research, 2017, 37, 3751-3755.	0.5	5
44	Pharmacokinetic–pharmacodynamic modelling of acute Nâ€ŧerminal pro Bâ€ŧype natriuretic peptide after doxorubicin infusion in breast cancer. British Journal of Clinical Pharmacology, 2016, 82, 773-783.	1.1	12
45	Cardio-Oncology Training: A Proposal From the International Cardioncology Society and Canadian Cardiac Oncology Network for a New Multidisciplinary Specialty. Journal of Cardiac Failure, 2016, 22, 465-471.	0.7	54
46	Shared Risk Factors in Cardiovascular Disease and Cancer. Circulation, 2016, 133, 1104-1114.	1.6	926
47	Cardiovascular Complications of Hematopoietic Stem Cell Transplantation. Current Treatment Options in Cardiovascular Medicine, 2016, 18, 25.	0.4	39
48	Utility of high-sensitivity cardiac troponin T in patients receiving anthracycline chemotherapy. Vascular Health and Risk Management, 2015, $11,591$.	1.0	29
49	Angiotensin Converting Enzyme Inhibitors (ACEI) and doxorubicin pharmacokinetics in women receiving adjuvant breast cancer treatment. SpringerPlus, 2015, 4, 32.	1.2	8
50	Hematopoietic Stem Cell Transplantation in Patients with Systolic Dysfunction: Can It Be Done?. Biology of Blood and Marrow Transplantation, 2015, 21, 300-304.	2.0	25
51	Hematopoietic Cell Transplantation in Patients with Systolic Heart Failure: Can It be Done?. Biology of Blood and Marrow Transplantation, 2014, 20, S37.	2.0	0
52	Estimated number of prevalent cases of metastatic bone disease in the US adult population. Clinical Epidemiology, 2012, 4, 87.	1.5	184
53	Patient Satisfaction with Physician Discussions of Treatment Impact on Fertility, Menopause and Sexual Health among Pre-menopausal Women with Cancer. Journal of Cancer, 2012, 3, 217-225.	1.2	78
54	Quality of life appears similar between survivors of indolent and aggressive non-Hodgkin lymphoma. Leukemia and Lymphoma, 2011, 52, 2105-2110.	0.6	11

#	Article	IF	CITATIONS
55	Pathologic femur fractures after limb-sparing treatment of soft-tissue sarcomas. Journal of Cancer Survivorship, 2010, 4, 399-404.	1.5	23
56	Angiotensin converting enzyme inhibitors may be protective against cardiac complications following anthracycline chemotherapy. Breast Cancer Research and Treatment, 2010, 122, 585-590.	1.1	32
57	Monitoring and Preemptive Rituximab Therapy for Epstein-Barr Virus Reactivation after Antithymocyte Globulin Containing Nonmyeloablative Conditioning for Umbilical Cord Blood Transplantation. Biology of Blood and Marrow Transplantation, 2010, 16, 287-291.	2.0	72
58	Corticosteroid Dose as a Risk Factor for Avascular Necrosis of the Bone after Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 2010, 16, 1231-1236.	2.0	63
59	Post-transplant lymphoproliferative disorders following solid-organ transplantation. Expert Review of Hematology, 2010, 3, 35-44.	1.0	31
60	Positron emission tomography scanning in the setting of postâ€ŧransplant lymphoproliferative disorders. Clinical Transplantation, 2009, 23, 794-799.	0.8	40
61	<i>Malassezia < li>: is it a pulmonary pathogen in the stem cell transplant population?. Transplant Infectious Disease, 2009, 11, 313-317.</i>	0.7	18
62	Necrotizing leukoencephalopathy following CHOP chemotherapy. Leukemia Research, 2008, 32, 1611-1614.	0.4	3
63	Rituximab therapy is effective for posttransplant lymphoproliferative disorders after solid organ transplantation. Cancer, 2005, 104, 1661-1667.	2.0	128
64	Body mass index (BMI) and quality of life among long-term survivors of childhood acute lymphoblastic leukemia. F1000Research, 0, 10, 178.	0.8	0
65	Inadequate survivorship care after allogeneic hematopoietic cell transplantation: A retrospective chart review. F1000Research, 0, 7, 1389.	0.8	3